Orchid Pharma Limited (ORCHPHARMA) AI Stock Analysis

• Market Cap: ₹26.48B
• Dividend Yield: N/A
• Average Volume (3M): 10.21K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.28
• Revenue Growth: -9.23%
• EPS Growth: -56.08%
• Country: IN
• Employees: 871
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): -2.49
• Shares Outstanding: 50,719,105
• 10 Day Avg. Volume: 2,303
• 30 Day Avg. Volume: 10,213
• PEG Ratio: 12.87
• Price to Book (P/B): 3.13
• Price to Sales (P/S): 4.31
• P/FCF Ratio: -30.33
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): 21.1
• Revenue Forecast (FY): ₹15.09B

• Rating: 54 Neutral
• Price Target: ₹488.00 ▼(-38.61% Downside)
• Action: Reiterated Date: 03/05/26
• Date: Action: Reiterated 03/05/26

The score is supported by improving profitability and a strong, low-leverage balance sheet, but is meaningfully reduced by negative free cash flow and weak cash conversion. Technicals are bearish with the stock trading below major moving averages and negative MACD, and valuation is pressured by an extremely high P/E with no dividend yield data.

Positive Factors

Low leverage and strong equity base

A 75.08% equity ratio and 0.14 debt-to-equity signal low financial leverage, which provides durable resilience to industry shocks, supports credit access for funding regulatory approvals or capacity expansion, and limits interest burden, preserving cash for strategic use over months.

Negative Factors

Negative free cash flow

A negative free cash flow position constrains the company's ability to fund capex, pay suppliers, or invest in regulatory filings without outside financing. If persistent, this limits strategic flexibility, increases financing costs, and can impair long-term capacity expansion or product registrations.

Orchid Pharma Limited Business Overview & Revenue Model

Company Description

Orchid Pharma Limited, a pharmaceutical company, engages in the development, manufacture, and marketing of active pharmaceutical ingredients, bulk actives, finished dosage formulations, and nutraceuticals in India. Its active pharmaceutical ingred...

Read more

Orchid Pharma Limited, a pharmaceutical company, engages in the development, manufacture, and marketing of active pharmaceutical ingredients, bulk actives, finished dosage formulations, and nutraceuticals in India. Its active pharmaceutical ingred...

How the Company Makes Money

Orchid Pharma Limited primarily makes money by selling pharmaceutical products and related services. Key revenue streams typically include: (1) sales of APIs to other drug manufacturers; (2) sales of finished dosage formulations (branded or generi...

Read more

Orchid Pharma Limited primarily makes money by selling pharmaceutical products and related services. Key revenue streams typically include: (1) sales of APIs to other drug manufacturers; (2) sales of finished dosage formulations (branded or generi...

Orchid Pharma Limited Financial Statement Overview

Breakdown	TTM	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Income Statement
Total Revenue	8.21B	9.22B	8.19B	6.66B	5.60B	4.50B
Gross Profit	3.27B	3.55B	1.36B	706.89M	2.32B	2.09B
EBITDA	1.02B	1.45B	1.42B	1.43B	621.38M	650.03M
Net Income	522.57M	996.57M	921.66M	463.18M	-19.51M	-1.17B
Balance Sheet
Total Assets	17.22B	16.88B	15.54B	12.25B	11.11B	12.37B
Cash, Cash Equivalents and Short-Term Investments	1.50B	1.83B	45.24M	275.21M	48.27M	315.15M
Total Debt	2.82B	1.75B	1.35B	3.31B	2.68B	4.53B
Total Liabilities	4.48B	4.21B	3.84B	5.37B	4.63B	5.84B
Stockholders Equity	12.74B	12.67B	11.69B	6.89B	6.47B	6.53B
Cash Flow
Free Cash Flow	-1.47B	-1.31B	611.77M	-665.75M	780.71M	229.82M
Operating Cash Flow	115.10M	192.15M	1.26B	183.38M	924.75M	235.86M
Investing Cash Flow	-906.39M	-269.31M	-3.12B	-312.14M	1.13B	672.05M
Financing Cash Flow	1.00B	252.22M	1.67B	311.66M	-2.17B	-1.65B

Orchid Pharma Limited Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 794.90
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:ORCHPHARMA, the sentiment is Negative. The current price of 794.9 is above the 20-day moving average (MA) of 523.56, above the 50-day MA of 617.58, and above the 200-day MA of 722.64, indicating a bearish trend. The MACD of -33.45 indicates Negative momentum. The RSI at 41.91 is Neutral, neither overbought nor oversold. The STOCH value of 28.78 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:ORCHPHARMA.

Orchid Pharma Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
RPGLIFE	76 Outperform	₹31.80B	43.39	―	0.85%	―	―
ADVENZYMES	65 Neutral	₹30.55B	19.90	―	1.70%	14.11%	7.47%
GUFICBIO	57 Neutral	₹29.06B	67.80	―	0.03%	7.78%	-34.68%
MOREPENLAB	57 Neutral	₹20.81B	20.54	―	0.49%	-0.29%	-29.04%
ORCHPHARMA	54 Neutral	₹26.48B	-76.20	―	―	-9.23%	-56.08%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%